Vertex Pharmaceuticals’ second quarter reflected strong commercial momentum, with management highlighting the performance of its cystic fibrosis (CF) portfolio and accelerating uptake of newer products like CASGEVY and JOURNAVX. CEO Reshma Kewalramani attributed revenue growth to “the strength of our cystic fibrosis portfolio and the growing contributions from our newer products,” while also emphasizing progress in regulatory and clinical milestones. Management specifically noted that ALYFTREK and TRIKAFTA continued to drive CF revenue, and that European launches benefitted from fewer monitoring requirements.
Is now the time to buy VRTX? Find out in our full research report (it’s free for active Edge members).
Vertex Pharmaceuticals (VRTX) Q2 CY2026 Highlights:
- Revenue: $3.33 billion vs analyst estimates of $3.19 billion (12.5% year-on-year growth, 4.6% beat)
- Adjusted EPS: $4.73 vs analyst expectations of $4.75 (in line)
- Adjusted Operating Income: $1.42 billion vs analyst estimates of $1.37 billion (42.7% margin, 3.9% beat)
- The company slightly lifted its revenue guidance for the full year to $13.15 billion at the midpoint from $13.03 billion
- Operating Margin: 37.4%, down from 38.8% in the same quarter last year
- Market Capitalization: $125.7 billion
While we enjoy listening to the management’s commentary, our favorite part of earnings calls is the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From Vertex Pharmaceuticals’s Q2 Earnings Call
- Salveen Richter (Goldman Sachs): Asked about the Phase II/III OLYMPUS study dose selection for Pove in membranous nephropathy and bottlenecks in JOURNAVX’s payer dynamics. CEO Reshma Kewalramani clarified the Data Safety Monitoring Board’s role in dose selection and Duncan McKechnie highlighted ongoing efforts to secure broader access for JOURNAVX.
- Geoffrey Meacham (Citibank): Inquired about desired clinical outcomes for next-generation CF therapies and payer feedback on JOURNAVX in diabetic peripheral neuropathy. Kewalramani said efficacy and safety are the main goals, with further data and payer perspectives expected in coming quarters.
- Jessica Fye (JPMorgan): Asked about expected differentiation on eGFR endpoints for new IgAN treatments. Kewalramani explained that long-term benefits will depend on time to end-stage renal disease and the ability to achieve deeper reductions in proteinuria and hematuria.
- Cory Kasimov (Evercore ISI): Sought clarity on interim analysis criteria for inaxaplin in AMPLITUDE and accelerated approval. Kewalramani said the FDA agreement focuses on 1-year GFR as the primary endpoint for the interim analysis.
- Mohit Bansal (Wells Fargo): Queried prescription duration trends for JOURNAVX. McKechnie noted average durations have remained stable at around 10–11 days per prescription, split between hospital and retail settings.
Catalysts in Upcoming Quarters
In coming quarters, the StockStory team will be watching (1) the pace of ALYFTREK adoption and label expansions in CF, (2) launch execution and patient uptake for CASGEVY and JOURNAVX, and (3) regulatory progress and launch timing for Pove in IgAN and the integration of Crinetics’ assets. Progress in clinical data readouts for next-generation CF and renal assets will also be key signposts.
Vertex Pharmaceuticals currently trades at $496.00, up from $470.72 just before the earnings. At this price, is it a buy or sell? Find out in our full research report (it’s free).
High-Quality Stocks for All Market Conditions
ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.
Find out which 5 stocks it’s flagging this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+214% between June 2020 and June 2025). Find your next big winner with StockStory today.
